No abstract

No abstract

No abstract

Life cycle management (LCM) is frequently described as a holistic sustainability perspective along the product chain. It has mainly been a company internal practice. However, recent developments reveal a new type of LCM where companies collaborate in product‐chain‐specific initiatives. This raises questions concerning why corporations extend “corporate LCM” toward “product chain LCM”. Here, we explore rationales and challenges for corporations engaging in one such coalition: The Sustainable Transport Initiative. The study covers five companies in different product chain positions and practitioners in different corporate functions. The results show a broad range of rationales for engaging in product chain LCM, related both to self‐interest and a shared interest in the product chain. The importance of the “business case,” both for the individual companies and the product chain, is identified. The importance of sustainability managers as actors and as facilitators in discussions between managers from different corporate functions is also identified.

differ from those of serum creatinine in patients with normal preoperative kidney function. Methods:We compared changes in serum levels of creatinine and cystatin C by measuring them serially in 19 patients undergoing CPB. Within-patient differences for serum creatinine and serum cystatin C were compared by repeated measures ANOVA.Results: Serum creatinine and cystatin C levels showed significant correlation with each other.Both biomarkers showed a significant decrease after CPB, but their serum concentrations reverted to pre-CPB levels within 12 hours. Serum levels of serum creatinine remained unchanged from baseline levels throughout 72 hours post-CPB. In contrast, serum cystatin C levels rose further, and became significantly higher compared to baseline within 48 hours. Serum cystatin C remained significantly elevated at 48 and 72 hours post-CPB. Conclusions:Processes that determine the serum concentrations of serum creatinine and cystatin C in the post-CPB period affect the two biomarkers differently, suggesting that the two are not interchangeable as diagnostic markers of glomerular filtration rate. Future studies are needed to examine if these discrepancies are related to differences in their production rates, in their ability to detect small changes in GFR, or to a combination of these, and to determine the effect of such differences on the diagnostic and prognostic accuracy of the two biomarkers.